LUND, Sweden, Sept. 28, 2018 /PRNewswire/ -- Immunovia
announced recently that a new study confirms that IMMray™ blood
test successfully addresses one of the major challenges in
autoimmune testing.
The capability of IMMray™ biomarker signatures to diagnose CCP
negative rheumatoid arthritis patients with an accuracy over 90% is
a remarkable breakthrough. These exceptionally good results
together with the two earlier reported studies showing very high
accuracies for the differential diagnosis of the four main
autoimmune diseases - rheumatoid arthritis, systemic lupus
erythematosus, Sjögren´s syndrome and systemic vasculitis (press
release March 7, 2017 and press
release January 12, 2017), resulted
in a strategic focus on rheumatoid arthritis.
Immunovia has since the announcement of these results worked
diligently to design studies in collaboration with the company's
Key Opinion Leader network to further verify and validate these
results and commence development of a commercial assay for this
important diagnostic unmet need.
The telephone conference will cover Immunovia's autoimmune
diseases strategy presented by Mats
Grahn, CEO, Immunovia and Laura
Chirica, CCO, Immunovia. The Q&A session will end the
call.
To attend, please dial-in at one of the numbers below
from:
Participant dial in number
SE: +46856642662
BE: +3224040635
CH: +41225675548
DE: +4969222229046
DK: +4535445579
FR: +33170750712
UK: +442030089801
NL: +207168416
NO: +4723500254
US: +18557532235
For questions as well as for timing of interviews:
ir@immunovia.com
On the Immunovia website under Investors/Audio Gallery
(https://immunovia.com/investors/audio-gallery/) there will be an
MP3 file for those who want to listen to the conference call later,
the file is available within two hours of the end of the conference
call.
For further information, please contact:
Mats Grahn
Chief Executive Officer, CEO, Immunovia
Tel.: +46-70-5320230
Email: mats.grahn@immunovia.com
About Immunovia
Immunovia AB was founded in 2007 by investigators from the
Department of Immunotechnology at Lund University and CREATE Health, the Center
for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to
decipher the wealth of information in blood and translate it into
clinically useful tools to diagnose complex diseases such as
cancer, earlier and more accurately than previously possible.
Immunovia´s core technology platform, IMMray™, is based on antibody
biomarker microarray analysis. The company is now performing
clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood based test for early
diagnosis of pancreatic cancer. In the beginning of 2016, the
company started a program focused on autoimmune diseases
diagnosis, prognosis and therapy monitoring.
(Source: www.immunovia.com)
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
About Rheumatoid Arthritis (RA)
Rheumatoid arthritis is a long-term condition that causes pain,
swelling and stiffness in the joints. The
symptoms usually affect the hands, feet and wrists. There may
be periods where symptoms become worse, known as flare-ups or
flares. A flare can be difficult to predict, but with
treatment it's possible to decrease the number of flares and
minimise or prevent long-term damage to the joints. Some people
with rheumatoid arthritis also experience problems in
other parts of the body, or more general symptoms such as
tiredness and weight loss.
In US and Europe, 5-7 Million
is the estimated number of patients living with RA and more than
250.000 new cases are diagnosed every year. Many more than these
who actually have RA need to be tested since overlapping symptoms
to early stage RA due to other causes are common. Due to its large
patient population, RA leads to substantial costs for individual
patients and healthcare systems as a result of symptoms, loss of
productivity, long-term co-morbidities, and hospitalisation. The
annual economic burden of RA in the US exceeds $19 billion, based on direct costs such as
hospitalisation, treatment, and loss of productivity.
Recent studies showed that as many as 51% of patients with
suspected autoimmune or immune disorders are initially
misdiagnosed, in part because of ambiguous laboratory test results.
Clinicians warn that misdiagnosis of systemic autoimmune diseases
can have serious consequences. Currently the gold standard is to
test for anti-cyclic citrullinated peptide (anti-CCP), an
auto-antibody present an estimated 70-75% of rheumatoid arthritis
patients.
The global market for RA testing is growing strongly and
estimated to reach Euros 2.5 billion
by 2024.
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/immunovia-ab/r/invitation-to-conference-call-regarding-immunovia-s-autoimmune-diseases-strategy-on-october-8--2018,c2630792
The following files are available for download:
http://mb.cision.com/Main/13121/2630792/917708.pdf
|
Press release
Telephone conference RA strategy
|
View original
content:http://www.prnewswire.com/news-releases/invitation-to-conference-call-regarding-immunovias-autoimmune-diseases-strategy-on-october-8-2018-300720872.html
SOURCE Immunovia AB